SARS-CoV-2-IN-33
Modify Date: 2025-08-22 08:44:33
SARS-CoV-2-IN-33 structure
|
Common Name | SARS-CoV-2-IN-33 | ||
|---|---|---|---|---|
| CAS Number | 299919-79-2 | Molecular Weight | 526.58 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H30N4O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SARS-CoV-2-IN-33SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 main protease (Mpro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19[1]. |
| Name | SARS-CoV-2-IN-33 |
|---|
| Description | SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 main protease (Mpro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19[1]. |
|---|---|
| Related Catalog | |
| Target |
COVID-19[1]. |
| In Vitro | SARS-CoV-2-IN-33 (0-40 µM) exhibits good antiproliferative activity in MCF-7, MDA-MB-231, HeLa and PC-3 cells[1]. Cell Proliferation Assay[1] Cell Line: MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293 Concentration: 0-40 µM Incubation Time: 48 h Result: Inhibited proliferation of MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293 cells with IC50 values of 5.45, 9.47, 22.86, 28.44, >40 and >40 μM, respectively. |
| References |
| Molecular Formula | C30H30N4O5 |
|---|---|
| Molecular Weight | 526.58 |